Casdin Capital 13F holdings, Q1 2024
Holdings as of March 31, 2024 · filings on SEC EDGAR · latest filing →
Casdin Capital disclosed 36 US equity positions worth $1.3bn in its Q1 2024 13F filing. The largest position was RVMD at 13.5% of the reported book, followed by LAB and BLFS. Against the Q4 2023 filing, it opened 3 new positions, added to 12 and reduced 4 among the top 36 holdings.
What did Casdin Capital own in Q1 2024? Top 36 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2023 |
|---|---|---|---|---|---|---|---|
| 1 | RVMD REVOLUTION MEDICINES INC | Healthcare | 13.5% | $181.1m | 5,617,599 | -2% | reduced |
| 2 | LAB STANDARD BIOTOOLS INC | Healthcare | 12.5% | $167.8m | 61,907,605 | 5059% | added |
| 3 | BLFS BIOLIFE SOLUTIONS INC | Healthcare | 12.0% | $161.5m | 8,707,165 | 0% | held |
| 4 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 10.3% | $138.4m | 1,069,000 | 6% | added |
| 5 | RLAY RELAY THERAPEUTICS INC | Healthcare | 4.6% | $61.6m | 7,423,574 | 0% | held |
| 6 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 4.0% | $53.5m | 358,000 | 84% | added |
| 7 | AVIDITY BIOSCIENCES INC | 4.0% | $53.2m | 2,084,841 | 77% | added | |
| 8 | NTLA INTELLIA THERAPEUTICS INC | Healthcare | 3.8% | $51.6m | 1,875,000 | 29% | added |
| 9 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 3.6% | $47.9m | 1,116,867 | 2% | added |
| 10 | EXK EXACT SCIENCES CORP | Basic Materials | 3.3% | $44.9m | 650,000 | 55% | added |
| 11 | VERVE THERAPEUTICS INC | 3.0% | $40.6m | 3,059,094 | 2% | added | |
| 12 | TNYA TENAYA THERAPEUTICS INC | 2.6% | $35.2m | 6,732,971 | 6% | added | |
| 13 | ILMN ILLUMINA INC | Healthcare | 2.5% | $34.1m | 248,000 | -21% | reduced |
| 14 | 2655787D BLUEPRINT MEDICINES CORP | 2.3% | $31.0m | 326,378 | 0% | held | |
| 15 | WGS GENEDX HOLDINGS CORP | Healthcare | 2.1% | $28.6m | 3,136,411 | 1% | added |
| 16 | NGNE NEUROGENE INC | 2.0% | $26.7m | 524,616 | 0% | held | |
| 17 | DNLI DENALI THERAPEUTICS INC | Healthcare | 2.0% | $26.7m | 1,300,000 | 0% | held |
| 18 | 4D MOLECULAR THERAPEUTICS IN | 1.9% | $25.5m | 800,000 | -23% | reduced | |
| 19 | BEAM BEAM THERAPEUTICS INC | Healthcare | 1.7% | $22.3m | 675,000 | 28% | added |
| 20 | VCYT VERACYTE INC | Healthcare | 1.4% | $19.0m | 857,904 | – | new |
| 21 | PLRX PLIANT THERAPEUTICS INC | Healthcare | 1.1% | $14.9m | 1,000,000 | -37% | reduced |
| 22 | IPSC CENTURY THERAPEUTICS INC | Healthcare | 1.0% | $13.4m | 3,206,380 | 0% | held |
| 23 | 2SEVENTY BIO INC | 0.8% | $10.7m | 2,000,000 | 69% | added | |
| 24 | ABCL ABCELLERA BIOLOGICS INC | Healthcare | 0.8% | $10.7m | 2,360,129 | 0% | held |
| 25 | TNGX TANGO THERAPEUTICS INC | Healthcare | 0.7% | $9.4m | 1,188,349 | 0% | held |
| 26 | CDXS CODEXIS INC | Healthcare | 0.5% | $7.0m | 2,000,000 | 0% | held |
| 27 | ABSI ABSCI CORPORATION | 0.4% | $5.5m | 973,260 | 0% | held | |
| 28 | PACB PACIFIC BIOSCIENCES CALIF IN | Healthcare | 0.3% | $3.9m | 1,035,859 | 0% | held |
| 29 | KYTX KYVERNA THERAPEUTICS INC | 0.3% | $3.7m | 150,000 | – | new | |
| 30 | GLUE MONTE ROSA THERAPEUTICS INC | 0.3% | $3.6m | 510,882 | 0% | held | |
| 31 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 0.3% | $3.6m | 150,000 | 0% | held |
| 32 | PRME PRIME MEDICINE INC | 0.2% | $2.6m | 367,175 | 0% | held | |
| 33 | GINKGO BIOWORKS HOLDINGS INC | 0.1% | $1.7m | 1,459,747 | – | new | |
| 34 | EXSCIENTIA PLC | 0.1% | $1.2m | 213,900 | 0% | held | |
| 35 | SINGULAR GENOMICS SYSTEMS IN | 0.1% | $680.7k | 1,323,885 | 0% | held | |
| 36 | KRONOS BIO INC | 0.0% | $161.0k | 123,839 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.